Global Blood Plasma Fractionation Market Size By Product, By Application, By Geographic Scope And Forecast

Blood Plasma Fractionation Market Size And Forecast

Blood Plasma Fractionation Market size was valued at USD 29.0 Billion in 2023 and is projected to reach USD 45.11 Billion by 2030, growing at a CAGR of 6.9% during the forecast period 2024-2030.

Global Blood Plasma Fractionation Market Drivers

The market drivers for the Blood Plasma Fractionation Market can be influenced by various factors. These may include

• Increasing Demand for Plasma-Derived Medicinal Products (PDMPs) The market for pharmaceuticals derived from plasma is growing. Blood plasma fractionation is necessary because the market for plasma-derived pharmaceuticals, such as albumin, clotting factors, and immunoglobulins, is growing. Hemophilia, liver ailments, immunodeficiency disorders, and other medical conditions are treated with the use of PDMPs.
• Rising Frequency of Chronic Illnesses The need for plasma-derived treatments is increased by the rising frequency of chronic illnesses, including liver, immune system, and bleeding problems. The technique of blood plasma fractionation offers a way to create and extract vital therapeutic proteins that are utilized to treat various illnesses.
• Immunoglobulins’ Increasing Use One of the main products of blood plasma fractionation is immunoglobulins, which are used to treat infections, neurological conditions, and autoimmune illnesses. Blood plasma fractionation is a growing market driven by the increasing medicinal applications of immunoglobulins.
• Increasing Senior Population The world’s aging population is a factor in the rise in age-related illnesses and ailments that call for treatments derived from plasma. Products generated from plasma are in greater demand since the aged population frequently suffers from chronic illnesses and immune system problems.
• Improvements in Blood Plasma Fractionation Technologies The yield and efficiency of the fractionation process are increased by continuous improvements in blood plasma fractionation technologies. The manufacturing of superior plasma-derived products helps to address the increasing demand for therapies by utilizing improved technologies.
• Technological Advancements in Fractionation Processes The advent of recombinant therapies has increased therapeutic choices, even though plasma-derived products are still necessary. A variety of therapeutic proteins that meet various medical needs can be produced by blood plasma fractionation and recombinant technology.
• Emergence of Recombinant Therapies Increasing Capital Allotted to Facilities for Plasma Fractionation In order to boost production capacity, there is a growing investment being made in both the development of new and the expansion of current plasma fractionation facilities. This thereby encourages the market to offer a wider variety of items developed from plasma.
• Increasing Investments in Plasma Fractionation Facilities Increased Recognition and Identification of Uncommon Illnesses Increased demand for specialist medicines, many of which are made from blood plasma, is driven by advances in awareness of and diagnostic capabilities for uncommon disorders. For uncommon diseases with potentially few therapeutic choices, blood plasma fractionation is essential to the provision of treatment.
• Global Blood Plasma Shortages The demand for goods generated from plasma frequently exceeds supply, resulting in shortages of blood plasma on a global scale. Companies that fractionate blood plasma have the chance to grow their production capabilities in response to this scarcity and fulfill the growing demand for therapies generated from plasma.
• Raising Healthcare Expenditure The general rise in healthcare spending, from public and private sources, helps make plasma-derived treatments more accessible and affordable. Patients can now get vital plasma-derived products thanks to this financial support.

Global Blood Plasma Fractionation Market Restraints

Several factors can act as restraints or challenges for the Blood Plasma Fractionation Market. These may include

• Strict Regulations Manufacturers face difficulties in adhering to the strict regulations governing plasma-derived products. The time and resources required to comply with regulations and secure permits can be substantial, which can hinder the pace of product development and market launch.
• High Operational Costs The processes involved in blood plasma fractionation are intricate and resource-intensive. The collection, processing, and fractionation of plasma come with high operational costs that might affect manufacturers’ profit margins. The total cost of operations is increased by the requirement for specialized facilities and qualified workers.
• Limited Plasma Donation Voluntary plasma donation is the only source of plasma availability. Inadequate donor incentives, logistical difficulties, and low awareness could lead to insufficient plasma supplies. The market may experience shortages as a result of this scarcity, which may limit the creation of items developed from plasma.
• Risk of Blood-Borne Infections Although plasma-derived products are subject to stringent screening procedures, there is little chance of blood-borne infection transmission. Even though it is uncommon, how this danger is perceived can have an impact on public trust and adoption of medicines generated from plasma.
• Competition from Recombinant Therapies Recombinant technologies have made therapeutic protein production more feasible and may lessen the market for some plasma-derived products. Traditional blood plasma fractionation products’ market share may be impacted by competition from recombinant medicines.
• Economic Downturns Financial unpredictability and economic downturns can affect patient affordability and healthcare expenditures. The availability of medicines produced from plasma could be impacted by government and individual cuts to healthcare spending, which would restrict market expansion.
• Consent Issues and Ethical Concerns In areas where paying for plasma donation is permitted, ethical questions about the commercialization of items obtained from human plasma may come up. Getting donors’ informed consent and maintaining ethical standards are important issues.
• Global Supply Chain Disruptions The blood plasma fractionation business depends on donations of plasma as well as a global supply chain for basic materials. Natural catastrophes, pandemics, or geopolitical events can all cause supply chain disruptions that affect plasma availability and production.
• technology and Infrastructure Deficits In certain areas, the development of sophisticated plasma fractionation facilities may be impeded by technology and infrastructure deficiencies. Local manufacturers may find their possibilities limited by restricted access to state-of-the-art technologies and infrastructure.
• Public Perception and Stigma Although plasma-derived therapies play a vital role in treating a range of medical illnesses, plasma donation and the usage of goods generated from plasma may still be stigmatized. Patient acceptability and donor engagement may be impacted by public perception and misinformation.

Global Blood Plasma Fractionation Market Segmentation Analysis

The Global Blood Plasma Fractionation Market is Segmented on the basis of Product, Application, And Region.

 By Product

•  Immunoglobulins (Igs) The largest sector consists of subcutaneous immunoglobulins (SCIg) for long-term therapy and intravenous immunoglobulins (IVIg) for immunological deficits and autoimmune disorders.
• Albumin Adds much to market value; used for burns, albumin deficit, and critical care.
• Coagulation Factor Concentrates (CFCs) Consistently increasing, CFCs are vital for treating bleeding diseases such as hemophilia.
• Additional Items Among the products that address particular medical needs are fibrinogen, protein C concentrates, and alpha-1 antitrypsin.

By Application

•  Neurology Due to the use of Igs in the treatment of autoimmune neurological illnesses such Guillain-Barre syndrome, neurology has the largest application segment.
•  Immunology The treatment of immunodeficiencies and autoimmune disorders places a significant demand on immunoglobulins and other plasma derivatives.
•  Hematology The treatment of hemophilia and other bleeding diseases is greatly aided by CFCs, which is propelling market expansion.
• Critical Care To treat shock, burns, and hypoalbuminemia, albumin is widely used in critical care settings.
• Additional Uses Plasma derivatives are becoming more popular in disciplines such as pulmonology, rheumatology, and even regenerative medicine.

By Region

• North America
• Asia-Pacific
• Latin America
• Middle East & Africa
• Europe

Key Players

The major players in the Blood Plasma Fractionation Market are

• CSL Behring (Australia)
• Octapharma (Switzerland)
• Takeda Pharmaceutical Company Limited (Japan)
• Grifols, S.A. (Spain)
• Kedrion S.p.A. (Italy)
• LFB S.A. (France)
• ADMA Biologics Inc. (US)
• Sanquin Blood Supply Foundation (Netherlands)
• China Biologic Products Holdings Inc. (China)
• GC Pharma (Korea)

Report Scope

Top Trending Reports

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors• Provision of market value (USD Billion) data for each segment and sub-segment• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled• Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players• The current as well as the future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions• Includes an in-depth analysis of the market of various perspectives through Porter’s five forces analysis• Provides insight into the market through Value Chain• Market dynamics scenario, along with growth opportunities of the market in the years to come• 6-month post-sales analyst support

Customization of the Report

• In case of any  please connect with our sales team, who will ensure that your requirements are met.